Plasma concentration of Paxlovid® (Nirmatrelvir/Ritonavir) in a clinical setting of Covid-19 patients: evaluation and approach for therapy optimization via therapeutic drug monitoring (TDM)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031391

Enrollment

Registered

2023-03-03

Start date

2022-11-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1

Interventions

Group 1: Adults of any gender with ability for informed consent and indication for Paxlovid®. After given informed consent, simultaneous quantifications of trough levels of Nirmatrelvir/Ritonavir by L

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: No further specific criteria

Exclusion criteria

Exclusion criteria: Unability for informed consent

Design outcomes

Primary

Measure	Time frame
Simultaneous quantification of plasma concentration of Paxlovid® (Nirmatrelvir/Ritonavir) by LC-MS/MS, at most 3 samples per patient as trough levels	—

Secondary

Measure	Time frame
Plasma concentration of co-medication	—

Countries

Germany

Contacts

Public ContactDirk O. Stichtenoth

Institut für Klinische Pharmakologie, Medizinische Hochschule Hannover

Stichtenoth.dirk@mh-hannover.de+49 511 532 2820

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026